The abstract is read at the publisher; the summary is JClub's.
SLC6A8-driven creatine accumulation is a conserved feature of chemotherapy-persisting acute myeloid leukemia, and SLC6A8 loss promotes immune remodeling under T cell pressure.
- Why it matters: Chemotherapy can leave persisting AML states, but how these metabolic adaptations influence immune evasion is unclear.
- What they did: Using stable-isotope tracing and genetic perturbations in mouse and human AML models, the study attributes creatine buildup mainly to SLC6A8-mediated uptake rather than de novo synthesis.
- The result: SLC6A8 is dispensable for proliferation and chemotherapy resistance, yet it strongly promotes leukemia persistence under T cell pressure by restraining cytokine-driven STAT1 signaling and antigen-presentation programs (including MHC-II, CD40, and CD80).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.